| Predicate |
Object |
| assignee |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_3da3b6984d156d898fcd47b2b22fc55a |
| classificationCPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P3-10
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P3-04
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P3-06
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-685
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P43-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P3-00 |
| classificationIPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-685 |
| filingDate |
2015-01-16-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| grantDate |
2019-04-09-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| inventor |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_f75250b5547085c689576138060b348b |
| publicationDate |
2019-04-09-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber |
US-10251897-B2 |
| titleOfInvention |
GLUT4 endocytosis inhibitor |
| abstract |
The present invention provides a therapeutic drug for diabetes containing 1,2-dioleoyl-sn-glycerol-3-phosphoethanolamine (DOPE) as an active ingredient, particularly a therapeutic drug for diabetes that exhibits a GLUT4 endocytosis suppressive action by suppressing activation of PKCĪ± and the like. |
| priorityDate |
2014-01-17-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type |
http://data.epo.org/linked-data/def/patent/Publication |